论文部分内容阅读
骨髓增生异常综合征(MDS)是以无效造血和克隆性造血干细胞异常为特点的一组疾病,目前尚无令人满意的治疗方法。氨磷汀是一种磷酸氨基硫醇前体药物,在细胞内去磷酸后释放出游离硫醇,在化疗和放疗过程中可以选择性保护正常组织,其中包括造血干/祖细胞。1997年有人开始试用氨磷汀治疗骨髓增生异常综合征,由于用药剂量、治疗方案和病例的不同,各临床试验间疗效差异较大。本文对氨磷汀治疗MDS的治疗发展经过、治疗方案、单药和联合用药的疗效、用药指征和不良反应等相关内容做一小结。
Myelodysplastic syndrome (MDS) is a group of diseases characterized by ineffective hematopoiesis and clonal hematopoietic stem cell abnormalities. There are currently no satisfactory treatments. Amifostine is a phosphoramidothiol prodrug that releases free thiols after intracellular dephosphorylation and selectively protects normal tissues during chemotherapy and radiotherapy, including hematopoietic stem / progenitor cells. 1997 people began to try amifostine treatment of myelodysplastic syndrome, due to the dosage, treatment options and cases of different clinical trials between the larger differences in efficacy. This article on the treatment of amifostine in the treatment of MDS after the development of treatment options, the efficacy of single drug and combination therapy, drug indications and adverse reactions to make a summary.